IP Library Granted Patent US 10,023,628
Granted Patent B2
US 10,023,628 · App. 14/412,823 · Granted Jul 17, 2018

Cell line expressing single chain factor VIII polypeptides and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,023,628
App. No.
14/412,823
Granted
Jul 17, 2018
Kind
B2
Abstract

The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.

Claims (17)

1. An isolated cell line comprising a recombinant vector encoding a single chain FVIII polypeptide, wherein the single chain FVIII polypeptide comprises residues 20 to 1457 of SEQ ID NO: 8.

2. The cell line of claim 1 , wherein the single chain FVIII polypeptide further comprises a heterologous moiety.

3. A polynucleotide encoding the single chain FVIII polypeptide of claim 1 .

4. A vector comprising the polynucleotide of claim 3 .

5. The cell line of claim 1 , wherein the cell line is a mammalian cell line.

6. The cell line of claim 2 , wherein the heterologous moiety is a half-life extending moiety.

7. The cell line of claim 6 , wherein the half-life extending moiety is an immunoglobulin constant region or a portion thereof, albumin, albumin binding polypeptide, PAS, the C-terminal peptide (CTP) of the β subunit of human chorionic gonadotropin, polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin-binding small molecules, or combinations thereof.

8. The cell line of claim 1 , wherein the cell line further comprises a polynucleotide specific for a FVIII polypeptide processing enzyme.

9. The cell line of claim 1 , wherein the single chain FVIII polypeptide further comprises an immunoglobulin constant region or a portion thereof.

10. The cell line of claim 1 , wherein the single chain FVIII polypeptide further comprises albumin.

11. A polynucleotide encoding the single chain FVIII polypeptide and the half-life extending moiety of claim 6 .

12. A vector comprising the polynucleotide of claim 11 .

13. A polynucleotide encoding the single chain FVIII polypeptide and the immunoglobulin constant region or a portion thereof of claim 9 .

14. A vector comprising the polynucleotide of claim 13 .

15. An isolated cell line comprising a recombinant vector encoding the amino acid sequence as set forth in SEQ ID NO: 8.

16. A vector encoding the amino acid sequence as set forth in SEQ ID NO: 8.

17. A method for producing a single chain FVIII polypeptide comprising culturing the cell line of claim 1 under conditions sufficient for production of the single chain FVIII polypeptide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2017
From: BIOGEN MA INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 041817/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2015
From: LOW, SUSAN; DUMONT, JENNIFER A.; BITONTI, ALAN J.
To: BIOGEN IDEC MA INC.
Reel/Frame 035870/0845 →
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →